{
    "clinical_study": {
        "@rank": "38693", 
        "arm_group": {
            "arm_group_label": "Pegylated Interferon Alfa-2b", 
            "arm_group_type": "Experimental", 
            "description": "6.0 \u03bcg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 \u03bcg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)"
        }, 
        "brief_summary": {
            "textblock": "This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant\n      treatment for melanoma."
        }, 
        "brief_title": "A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Competent to self-administer the subcutaneous injections of PEG-IFN\n\n          -  Histologically documented involved regional lymph nodes of a primary cutaneous\n             melanoma or unknown primary, meeting the study's staging criteria\n\n          -  Had the primary melanoma completely resected with adequate surgical margins and\n             undergone operation for positive regional lymph nodes within 84 days of study start\n\n          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1\n\n          -  Adequate hepatic, renal and bone marrow function as defined by study parameters\n             obtained within 4 weeks prior to study start\n\n          -  For a female subject who is of childbearing potential or male participant with female\n             sexual partner who is of childbearing potential, agree to use acceptable methods of\n             contraception for at least 2 weeks prior to study start and continue until at least 6\n             months after last dose of study medication, or longer if dictated by local\n             regulations\n\n        Exclusion Criteria:\n\n          -  Mucous membrane melanoma or ocular melanoma\n\n          -  Known hypersensitivity to the components of study drug (including acetaminophen), or\n             its analogs\n\n          -  Evidence of distant or non-regional lymph node metastases or in-transit metastases\n\n          -  Disease that cannot be completely surgically resected\n\n          -  Prior malignancy within the past 5 years other than surgically cured non-melanoma\n             skin cancer or cervical carcinoma in situ\n\n          -  Severe cardiovascular disease, i.e. arrhythmias, requiring chronic treatment,\n             congestive heart failure or symptomatic ischemic heart disease\n\n          -  Hepatic decompensation\n\n          -  Thyroid dysfunction not responsive to therapy\n\n          -  Uncontrolled diabetes mellitus\n\n          -  Clinically active autoimmune disease\n\n          -  Clinically active and/or uncontrolled infection, including active hepatitis\n\n          -  Human immunodeficiency virus (HIV)\n\n          -  History of neuropsychiatric disorder requiring hospitalization\n\n          -  Actively abusing alcohol or drugs\n\n          -  Pregnant, lactating, or of reproductive potential and not using an effective means of\n             contraception\n\n          -  Medical condition requiring chronic systemic corticosteroids\n\n          -  Received any experimental therapy within 30 days prior to enrolling in this study\n\n          -  Received any prior chemotherapy, immunotherapy, hormonal or radiation therapy for\n             melanoma\n\n          -  Previously received interferon-\u03b1 for any reason\n\n          -  Known serious hypersensitivity reaction to PEG-IFN or interferon alfa-2b"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155322", 
            "org_study_id": "4031-400"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pegylated Interferon Alfa-2b", 
                "description": "6 \u03bcg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks", 
                "intervention_name": "Pegylated Interferon Alfa-2b", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Pegylated Interferon Alfa-2b", 
                "description": "3 \u03bcg/kg, weekly dosing, subcutaneous administration, Maintenance Phase - Up to 12 months after the 1st dose of PEG-IFN at 6 \u03bcg/kg", 
                "intervention_name": "Pegylated Interferon Alfa-2b", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Peginterferon alfa-2b", 
                "Reaferon"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Pegylated Interferon Alfa-2b in AJCC Stage III (TxN1-2M0) Melanoma Subjects After Regional Lymph Node Dissection in Russia", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants who experience an adverse event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 13 months"
            }, 
            {
                "measure": "Number of participants who discontinue study medication due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155322"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}